Insider Transaction Overview
According to recent regulatory filings with the Securities and Exchange Commission, David Young, acting in his capacity as President of Research & Development for Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), completed a purchase of company stock on April 30, 2026. The transaction consisted of 1,706 shares of common stock, acquired at an individual share price of $2.69. This specific acquisition represents a total capital outlay of $4,589.
The details of this trade were formally documented in a filing submitted to the SEC on May 1, 2026. Such filings are essential for transparency regarding how corporate officers manage their personal stakes in the organizations they lead.
Current Shareholding Structure
Following the completion of this transaction, Mr. Young's direct holdings in Processa Pharmaceuticals common stock have risen to a total of 13,813 shares. In addition to these direct holdings, his overall interest in the company is further comprised of several indirect holdings managed through different entities:
- The Young-Plaisance Revocable Trust holds 1,242 shares.
- Family Entities hold a total of 432 shares.
- CorLyst, LLC maintains an indirect holding of 742 shares.
Key Market Observations
The transaction highlights specific movements within the pharmaceutical and biotechnology sectors. When executives in research-focused roles engage in direct stock purchases, it serves as a data point for analyzing internal equity distributions.
- Executive Participation: The purchase by the President of Research & Development adds to the documented holdings of the company's leadership.
- Sector Impact: Transactions of this nature occur within the broader biotechnology market, where internal stakeholder activity is tracked by analysts monitoring Nasdaq-listed entities.
Risk and Uncertainty Factors
While the transaction provides clarity on current ownership levels, certain factors remain inherent to the context of such filings:
- Transaction Scale: The total value of this specific purchase was $4,589, which represents a single data point in the broader context of company valuation.
- Reporting Lag: While the trade occurred on April 30, it was reported to the SEC on May 1, illustrating the standard timing between execution and public disclosure.